NDAORALTABLET
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19
Data completeness
5/8 — Partial
UBRELVY (ubrogepant) by AbbVie is calcitonin gene-related peptide receptor antagonists [moa]. First approved in 2019.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UBRELVY (ubrogepant) is an oral, small-molecule CGRP receptor antagonist approved in December 2019 for the acute treatment of migraine with or without aura in adults. It works by blocking calcitonin gene-related peptide signaling, a key pathway in migraine pathophysiology. This represents a novel non-triptan option for migraine patients seeking rapid symptom relief.
$0.315BPart D
Peak15.3 years to LOEThe product is at peak commercial maturity with $315M in annual Part D spending, suggesting a well-established brand team with moderate headcount for portfolio maintenance and market optimization.
Mechanism of Action
Calcitonin Gene-related Peptide Receptor Antagonists
Pharmacologic Class:
Calcitonin Gene-related Peptide Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (19)
Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants
Started Jul 2026
52 enrolled
Healthy Volunteer
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Started Jan 2026
189 enrolled
Migraine
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
Started Feb 2025
178 enrolled
Migraine
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
Started Sep 2024
43 enrolled
Migraine
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Started Sep 2024
496 enrolled
Migraine
Worked on UBRELVY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.